TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04786613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular 20 mg, 1.0% Hyaluronic Acid Injection
Description: Intra-articular 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular 32 mg, 1.6% Hyaluronic Acid Injection
Description: Intra-articular 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular 48 mg, 2.0% Hyaluronic Acid Injection
Description: Intra-articular 2,4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in single session will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
Study: NCT06152679

Intervention type: OTHER
Intervention: None - qualitative interviews
Description: Qualitative interviews with patients asking about their experience of day-case endourology.
Study: NCT05279118

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
Study: NCT06188676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Ciclofosfamida

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Ciclofosfamida

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Adriamycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide Phosphate
Description: Etopophos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Etopophos

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolonum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolonum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Chimeric Anti-CD20 Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Chimeric Anti-CD20 Antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Oncovin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Oncovin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: G-CSF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: PEG-filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: PEG-filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 40 mg in 4 ml Injection
Description: Opdivo
Study: NCT05712837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% TRICHLOROACETIC ACID
Description: Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% salicylic acid
Description: Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
Study: NCT05868278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training method intervention
Description: Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
Study: NCT05314179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doula - Patient engagement
Description: Ubuntu ambassador/Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2) practical assistance, 3) family support, and/or 4) legacy building projects as per study protocols.~The nature and type of visits will be determined by the patient and doula.
Study: NCT05825300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email message
Description: Email message encourages patients to donate blood

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email message
Description: Email message encourages patients to donate blood

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social responsibility
Description: Message specifies that there is a shortage of the patient's blood type
Study: NCT06337227

Intervention type: DIAGNOSTIC_TEST
Intervention: lncRNA signature analyses
Description: Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: lncRNA signature analyses
Description: Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: lncRNA signature analyses
Description: Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy
Study: NCT05546814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sodium algorithm
Description: Infants will receive sodium and follow a sodium supplementation schedule or algorithm. This means that based on the sodium levels collected from the samples (stool and urine) they will receive an increase or maintain the same amount to help
Study: NCT05096611

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attachment and Biobehavioral Catch up
Description: ABC is delivered by a trained parent coach. The parent coach provides information about parenting and child development. The focus is on providing support for parents of young children and improving the parent-child relationship.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch up Plus Depression Treatment
Description: ABC+D offers the same 10-sessions of parenting support that is provided by ABC and additionally provides weekly short videos that help mothers develop skills for coping with stress and regulating mood.
Study: NCT04728139

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: glypican 3
Description: Assessment of glypican 3 presence in colorectal cancer patients using ELISA
Study: NCT06377956

Intervention type: OTHER
Intervention: Observation without intervention
Description: Observation of gut length, food intake, fecal and urine calories, body composition, microbiota, metabolic rate, metabolomics.
Study: NCT05284955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF System
Description: The CardioMEMS HF System is a wireless pulmonary artery pressure monitor. We will use measurements from the device to guide medical heart failure therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard heart failure medical therapy
Description: Standard heart failure medical therapy as recommended by guidelines.
Study: NCT05888610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Outpost
Description: A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.
Study: NCT04996940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-cigarette product
Description: Participants will be randomized 1:1 to e-cigarette flavor order either:~1. tobacco e-cigarette~2. menthol e-cigarette

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-cigarette product
Description: Participants will be randomized 1:1 to e-cigarette flavor order either:~1. tobacco e-cigarette~2. menthol e-cigarette
Study: NCT05732805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-217
Description: Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCD-100
Description: Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05025462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement dose 15g/d
Description: Supplementation with 15g/day of SPF or Comparator

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement dose 15g/d
Description: Supplementation with 15g/day of SPF or Comparator

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement dose 7.5g/d
Description: Supplementation with 7.5g/d of SPF ou comparator

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement dose 7.5g/d
Description: Supplementation with 7.5g/d of SPF ou comparator
Study: NCT05338697

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
Study: NCT05536206

Intervention type: DEVICE
Intervention: Wireless and continuously monitoring
Description: Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge with data transmitted in real time to personnel at the hospital. Monitoring will last for a maximum of 72 hours.
Study: NCT05355129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TT-00920 Placebo
Description: Tablets
Study: NCT06032507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone lavage previous to cementation
Description: Bone lavage previous to cementation in total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone lavage previous to cementation
Description: Bone lavage previous to cementation in total knee arthroplasty
Study: NCT04814602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proglumide
Description: CCK receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proglumide
Description: CCK receptor antagonist
Study: NCT05733676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride
Description: Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride
Description: Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe
Study: NCT06156059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Bedtime Melatonin
Description: 100 mg oral suspension or capsule given at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Bedtime Melatonin
Description: 100 mg oral suspension or capsule given at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Bedtime Melatonin
Description: 100 mg oral suspension or capsule given at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Bedtime Melatonin
Description: 100 mg oral suspension or capsule given at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension or capsule
Description: Indistinguishable suspension or capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension or capsule
Description: Indistinguishable suspension or capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension or capsule
Description: Indistinguishable suspension or capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension or capsule
Description: Indistinguishable suspension or capsule
Study: NCT05286463

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bee venom gel phonophoresis
Description: a noncontact low-frequency pulsed ultrasound delivered through Bee Venom previously prepared gel as topical application using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low intensity ultrasound
Description: a noncontact low-frequency pulsed ultrasound delivered through plain gel only using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
Study: NCT05736419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered Post-Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered beginning on day +5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: The dose and schedule of ATG will be determined according to the nomogram in Appendix A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab on days -71, -58, -43, and -30.
Study: NCT05068921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
Study: NCT05815615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasma donation at different frequencies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasma donation at different frequencies

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plasmapheresis
Description: Plasma donation at different frequencies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasma donation at different frequencies
Study: NCT02376647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving pressure limited ventilation
Description: Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.~Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation
Description: Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
Study: NCT05638737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04800939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The experimental group will start with HT7 points and continue with SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Plasebo acupressure
Description: In the control group, the application will start with the points 1.5 cm around the HT7 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
Study: NCT05996367

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-dose involved-site radiotherapy
Description: Single-dose of 8 Gy at involved-site radiotherapy
Study: NCT05099289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtaCor EV-ICD Lead
Description: Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
Study: NCT04349007

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard meal
Description: local porridge with a vitamin and mineral sprinkle powder that will be mixed in after cooking

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: School food ready-to-use
Description: 80 gram per day sachet containing peanut paste with oil, sugar, cowpea, maize, and vitamin and minerals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: School food ready-to-use plus Milk
Description: 80 gram per day sachet containing peanut paste with oil, sugar, cowpea, non-fat dried milk and vitamin and minerals
Study: NCT05519553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support
Description: : 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline